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Adverse drug reactions are a common and important complication of drug therapy in
children. Over the past decade it has become increasingly apparent that genetically
controlled variations in drug disposition and response are important determinants of
adverse events for many important adverse events associated with drug therapy in
children. While this research has been difficult to conduct over the past decade technical
and ethical evolution has greatly facilitated the ability of investigators to conduct
pharmacogenomic studies in children. Some of this research has already resulted in
changes in public policy and clinical practice, for example in the case of codeine use by
mothers and children. It is likely that the use of pharmacogenomics to enhance drug safety
will first be realized among selected groups of children with high rates of drug use such as
children with cancer, but it also likely that this research will be extended to other groups
of children who have high rates of drug utilization and as well as providing insights into the
mechanisms and pathophysiology of adverse drug reactions in children.
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GENETICS AND CHILDHOOD DISEASE
The recent interest in personalized medicine has highlighted the
importance of genetic variability in the pathophysiology and out-
come of human disease (Weiss et al., 2008; Godman et al., 2013).
In the case of children, the influence of genetics on health has
been appreciated for many years; for example impact of con-
genital disease such as Down Syndrome was well known in the
nineteenth century—although the precise genetic basis of the dis-
ease was not described until 1959 (Down, 1866; Lejeune et al.,
1959). There are numerous other examples of genetically deter-
mined disease—such as Cystic Fibrosis and Duchenne Muscular
Dystrophy—whose substantial impact on children’s health, well-
being and life expectancy have been known to pediatricians for
many decades.
With respect to treatment, although many of the therapies that
we are familiar with have only been used fairly recently—since the
Therapeutic Revolution initiated by the discovery of the antibac-
terial activity of sulfanilamide in 1937—the potential that genetic
factors could influence therapeutic outcomes was in fact recog-
nized before that (Weinshilboum, 1987). Sir Archibald Garrod is
recognized as the father of medical genetics by virtue of being the
first investigator to recognize the potential importance of the fact
that people are biochemically unique individuals. He also made
the observation at the start of the last century that, in addition
to controlling key metabolic pathways, genetics was also likely to
influence variability in the response to patients to drugs (Knox,
1958).
This was confirmed in one of the landmark studies in pharma-
cogenetics, that being the research reported by David Price Evans,
Victor McKusick and colleagues at Johns Hopkins who in their
landmark study of isoniazid metabolism established that “fast”
and “slow” acetylator phenotypes were the result of genetic vari-
ation between these two populations (Evans et al., 1960). In this
paper, of the 291 subjects studied 82 were under the age of 20, of
whom 57 were under the age of 12 (Evans et al., 1960). This paper
also made the observation that the differences observed were the
result of genetic variations that were not age-dependent, suggest-
ing that what was important for adults would also be important
for children.
While this work and the observations of others provided
clear and compelling reasons that research toward understand-
ing how genetics influenced drug action and clearance would be
an important part of appreciating how to address variability in
drug response—both desired and undesired—in children, phar-
macogenomics has been a relative late comer to the forefront of
pediatric research. It is likely that this was due to several fac-
tors, some of which interact. One of the major driving forces
for pediatric pharmacology research—and, indeed for research
involving children in other disciplines—has been the appreciation
that ontogeny is an important element in the pathophysiology of
many childhood disorders (Choonara and Rieder, 2002; Kearns
et al., 2003; Hines, 2008; Dotta and Chukhlantseva, 2012; Kerkhof
and Hokken-Koelega, 2012; Sävendahl, 2012). It has been appre-
ciated for some time that an important determinant of drug
response in children is in fact developmentally-induced changes
in drug disposition related to maturation of pathways involved
in drug activation and clearance, with the more recent apprecia-
tion that the ontogeny of drug receptors and transporters may be
key elements in determining drug response in children (Kearns
et al., 2003; Neville et al., 2011; Dotta and Chukhlantseva, 2012).
As an example, in the fetus CYP3A7 is an important driver of
oxidative drug metabolism while there is very little CYP3A4 activ-
ity; after birth, the amount of CYP3A7 rapidly declines while
the activity of CYP3A4 steadily increases (Kearns et al., 2003;
Dotta and Chukhlantseva, 2012). Renal drug excretion in the fetus
is markedly reduced compared to older children; at birth term
www.frontiersin.org April 2014 | Volume 5 | Article 78 | 1
Rieder and Carleton Pharmacogenomics and ADRs in Children
infants have a third of the capacity for glomerular filtration on
a surface-area corrected basis compared to children at a year of
age (Dotta and Chukhlantseva, 2012). Failure to appreciate this
has lead to tragedy—for example, the Gray Baby Syndroe asso-
ciated with chloramphenicol treatment in neonates (Choonara
and Rieder, 2002). It is has been appreciated for several decades
that developmental determined variability in drug clearance and
response have had a major impact on drug safety in children
(Choonara and Rieder, 2002). Thus, it is not surprising that much
of the research conducted in pediatric pharmacology over the past
several decades has focused on understanding the ontogeny of
key determinants of drug activation, clearance response (Sumpter
and Anderson, 2009). As well, most of the genetic disorders his-
torically most relevant to child health were either chromosomal
polysomies (for example, Down Syndrome) or disorders that
are inherited by classical Mendelian or X-linked inheritance (for
example, Cystic Fibrosis or Duchenne Muscular Dystrophy); in
constrast, many pharmacogentically determined variations are
due to markedly more complex mechanisms as well as frequently
involving the interaction of several genes and gene products.
In addition to the issue of focus, there have been pragmatic
issues that have constrained investigation in pharmacogenomics
in children. The amount of blood needed to conduct studies—
and the cost required to then analyze this blood—have been
practical barriers that have historically constrained investiga-
tion in this area, notably among young children in whom there
are technical difficulties in obtaining blood and limitations in
terms of the volume of blood that can be drawn. In addition
to the technical issues, the conduct of pharmacogenomic studies
in children—indeed, the conduct of any research in children—
involves the ethical consideration that the person consenting is
not the person on whom the study is being conducted, and thus
issues such as minimal risk and benefit/risk assume a different
perspective in this population (Norbert and Roses, 2003; Avard
et al., 2009). Finally, a barrier to drug research in children in gen-
eral has been the perception—in fact, the myth—that drug use in
children is both infrequent and is largely confined to antibiotics
(Rieder et al., 2011).
While this challenges have been formidable, over the past
decade many of them have been addressed and in fact there are
now a number of pharmacogenomic studies in children under-
way (Stevens et al., 2013). The amount of sample needed for
studies has decreased dramatically, while there has been an even
more dramatic decrease in the cost and availability of genetic
analysis (Loo et al., 2010; Hawcutt et al., 2013). Additionally, the
availability of alternate sample sources for genetic studies—such
as saliva—has greatly facilitated genetic studies in populations
such as infants and toddlers (Loo et al., 2010). There has been
emerging work on developing consensus in the approach to phar-
macogenomic studies in children; recent work by our group has
demonstrated that parents in fact are supportive of pharmacoge-
nomic studies in children, with the proviso that this support
was dependent on parental understanding of the reason(s) for
the study and the potential benefit to their child and other chil-
dren (Zhang et al., in press). Finally, it is now appreciated that
in fact drug therapy in children is both common and complex—
as an example, a Canadian child is prescribed on average 4
prescriptions a year from a range of more than 2400 therapeutic
entities, while the use of psychotropic medications among ado-
lescents in the United States has been one of the fastest growing
trends in drug utilization over the past decade (Khaled et al., 2003;
Rieder et al., 2003; Jonas et al., 2013). For some children—notably
those with chronic disease—complex and frequently multi-drug
therapy constitutes one of the mainstays of treatment. Thus the
imperative for understanding sources of variability in drug use
among children—notably with respect to drug safety—is both
immediate and crucial.
GENETICS AND OPTIMAL DRUG THERAPY
The recent interest in understanding how genetics controls drug
disposition and response in children in turn leads to the consider-
ation of how this new knowledge can best be applied to improve
the care of children. There are a number of possibilities. Can
insights into the genetic regulation of drug response lead to the
identification of new therapeutic targets or to the more precise
manipulation of known targets? Can the knowledge as to how
genetics controls human drug variability be used to direct ther-
apy to specific conditions in which a better response is probable?
Can understanding genetic regulation of response and disposi-
tion of drugs in children be used to improve drug safety by better
understanding how adverse drug reactions develop, how these
reactions can be modified or prevented and which children are at
specific risk for adverse drug reactions?While all three approaches
should and are being pursued, it is likely that the most immedi-
ately fruitful results will come from applying pharmacogenomics
to enhancing drug safety (Becker and Leeder, 2010; Hawcutt et al.,
2013; Stevens et al., 2013).
ADVERSE DRUG REACTIONS IN CHILDREN
Pursuit of initiatives to improve drug safety in children argues
that this is a pressing and important issue (Choonara and Rieder,
2002). While the Therapeutic Revolution and the development of
specific therapy have been of unquestionable value in enhancing
the health and well-being of children and in providing clinicians
with unprecedented opportunities to cure and control common
child health problems, this has not been without a cost. In addi-
tion to economic costs—and drugs are the second or third most
expensive element in health care in many developed countries—
drug therapy is associated with the risk of adverse drug reactions.
Adverse drug reactions have been defined as “a response to a
drug which is noxious and unintended and which occurs at doses
normally used in man for prophylaxis, diagnosis, or therapy of
disease, or for themodification of physiologic function” (Edwards
and Aronson, 2000; Nebeker et al., 2004). Adverse drug event is a
more inclusive term which includes errors related to drug admin-
istration such as giving the wrong drug or wrong dose (Kaushal
et al., 2001).
Historically adverse drug reactions in children—typically in
the context of a therapeutic tragedy—have been and continue to
be major shapers of public policy on drug regulation (Choonara
and Rieder, 2002; Ciszkowski et al., 2009). As noted above, chil-
dren do in fact receive a number of medications—in our previous
work, we have shown that in a cohort of 1,000,000 children
there are on average 4 prescriptions written per child per year
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(Khaled et al., 2003; Rieder et al., 2003). What needs to be appre-
ciated is that the use of prescription drugs is in fact not evenly
distributed—while 65% of children receive either no or one pre-
scription per year, 25% of children account for 70% of drug use
(Khaled et al., 2003). These children are frequently children with
complex and/or chronic disorders such as cancer, epilepsy, or
asthma, and often are treated with multiple medications. As can
be appreciated, adverse drug reactions are likely to be much more
common among these children, and a number of studies have
demonstrated that there is a significant rate of adverse drug reac-
tions among children (Lazarou et al., 1998; Impicciatore et al.,
2001; Le et al., 2006; Kongkaew et al., 2008; Davies et al., 2009;
Aagaard et al., 2010; Sotomayor et al., 2010; Rieder, 2012). It
appears that there approximately a 5% risk of an adverse drug
reaction with most drugs used for the care of children, and
for some drugs—such as chemotherapeutic agents—this risk is
appreciably higher (Rieder, 2012) (Table 1).
It is important to appreciate that, while pharmacogenomics
may have much to offer in enhancing drug safety, it is likely that
these benefits will be largest among specific sub-sets of adverse
drug reactions. Adverse drug reactions can be classified by a
number of systems, but one of the most useful groups adverse
drug reactions as Type A (Predictable or Pharmacological) or
Type B (Unpredictable) (Table 2) (Rieder, 2012). While Type
A adverse drug reactions are more common, they are fre-
quently mild and often self-limited (Davies et al., 2009; Rieder,
2012). In contrast, while Type B adverse drug reactions are less
common, they are often more severe and are more likely to
result in serious morbidity or even mortality (Rieder, 2012).
Given that Type A adverse drug reactions can often be pre-
dicted from the known pharmacology of the drug, it is likely
that pharmacogenomics will be of more utility in helping to
address the problem of Type B adverse drug reactions. One
exception is codeine toxicity, which as discussed below is a
concentration-dependent toxicity related to the drug’s known
CYP2D6 pharmacogenomic variability in populations. An impor-
tant classification of adverse drug events that pharmacogenomics
has little relevance for are drug errors, which are due to indi-
vidual and system issues in drug prescribing, dispensing and
administration (Nebeker et al., 2004). In the case of drug errors,
educational and system approaches are most likely to be fruit-
ful in reducing the risk of these adverse drug events (Rieder,
2012).
The importance of enhancing drug safety in children is even
more telling given the drug approval process (Rieder, 2010). The
usual submission for a investigational new drug does not include
studies on children with the exception of drugs such as antibiotics,
and thus many of the drugs prescribed for children are prescribed
off-label, which is to say in populations and for indications that
are not part of the marketing approval granted by a drug regu-
latory agency (Castro-Pastrana and Carleton, 2011; Kimland and
Odlind, 2012). The paradox of this is that drugs which are shown
to be safe and effective in specific populations—often adults—are
then given to individual children, under circumstances in which
the optimal dose and adverse effect profilemay not be well defined
(Castro-Pastrana and Carleton, 2011). By better understanding
risk factors for adverse events—and potentially appreciating their
mechanisms—pharmacogenomics offers the potential for greatly
enhancing drug safety in children.
Historically there have been five recognized risk factors for
adverse drug reactions, of which several—extremes of age and
impairment of the organs of clearance—apply to children; more
recently, an additional two risk factors have been added, one of
which—certain genetic polymorphisms—is a direct indication of
the importance of pharmacogenomics in drug safety (Table 1)
(Rieder, 2012). Given the patterns of drug utilization in children,
there are certain groups of children for whom pharmacogenomics
is more likely to be of immediate benefit in improving drug safety.
CHILDHOOD CANCER
Cancer is one of the commonest causes of death for children
in developed countries, but also has been one of the major—
and often unsung—success stories of pediatric pharmacotherapy.
Over the past five decades, there has been remarkable over-
all success in terms of improved survival among children with
cancer (Armenian et al., 2013). However, the survival rates for
some cancers—such as brain tumors—have not improved to the
same degree, and over the past decade it has become increas-
ingly clear that long-term adverse effects of therapy are impacting
on the health and well-being of the survivors of childhood can-
cer (Rosoff, 2006; Armenian and Robinson, 2013). The rate of
adverse drug reactions in children with cancer is high andmany of
the most dreaded complications of childhood cancer are adverse
events directly related to drug therapy. These effects have sig-
nificant immediate and long-term impacts as well as affecting
health-related quality of life. (Fakhry et al., 2013). Interestingly,
Table 1 | Risk factors for adverse drug reactions in children.
Historical risk factors Currently accepted risk factors
History of a previous ADR History of a previous ADR
Extremes of age Extremes of age
Impairment of drug clearance Impairment of drug clearance
Polypharmacy Polypharmacy
Female Gender Female gender
Higher drug dose
Certain genetic polymorphisms
Modified from Rieder (2012).
Table 2 | Classification of adverse drug reactions.
Type A Type B
Predictable Unpredictable
Common Infrequent
Often mild, self-limited Often severe
Based on the drug’s
known pharmacology
Based on genetic or other factors
Dose-dependent No clear relationship to drug dose
Acts on drug’s site of
action or similar site
Unrelated to the site of drug action
Modified from Rieder (2012).
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among survivors of childhood cancer, health-related quality of life
is overall relatively high—except for those children who have sus-
tained co-morbidities, typically as a long-term adverse events of
therapy. In terms of frequency, this can be as many as two-thirds
of all survivors; follow-up studies have demonstrated that a quar-
ter of adult survivors of childhood cancer have serious chronic
health conditions related to their therapy, with 25% having three
or more chronic health problems (Rosoff, 2006). Given the com-
plexity of cancer therapy and the fact that many of the drugs used
are likely to be subject to genetically determined variability in dis-
position, childhood cancer would seem to be an area in which
there is likely to be more rapid uptake of pharmacogenomics to
enhance drug safety. Moreover, genetics is also a part of the care
of some children with cancer, for example using the Philadelphia
Chromosome (reciprocal translocation between chromosomes
9 and 22) to alter therapy—related to a different prognosis—
in children with acute lymphoblastic leukemia (Bhojwani et al.,
2009; Jabbour and Kantarjian, 2012).
Indeed, one of the first pharmacogenetic associations with
drug safety—the pharmacogentic variability in S-methylation
of thiopurines—was made in the setting of childhood can-
cer. Thiopurine Methyltransferase (TPMT) is a key enzyme
in the biotransformation of 6-mercaptopurine (Figure 1)
(Pacifici et al., 1991). 6-mercaptopurine is metabolized to a
active metabolites—6-thioguanine nucleotides—mediated by
hypoxanthine-guanine phosphoribosyltransferase (HGPRT)
while methylation by TPMT produces active metabolites
6-methylmercaptopurine and 6-methylmercaptopurine ribonu-
cleotides (Figure 1) (Weinshilboum et al., 1978). It has also
been appreciated that this drug is associated with significant
toxicity that is highly variable across populations (Weinshilboum
and Raymond, 1997). A key study in this area was published in
1980, when Drs. Weinshilbaum and Sladek at the Mayo Clinic
demonstrated marked variability in TPMT enzyme activity was
related to autosomal codominant inheritance for alleles coding
for low and high TPMT activity; of the subjects in the study,
FIGURE 1 | Metabolism of 6-Mercaptopurine (6-MP). Metabolism of
6-MP via Hypoxanthine-guanine Phosphoribosyltransferase produces active
Thioguanine nucleotide analogues while metabolism of 6-MP by Thiopurine
Methyltransferase produces inactive 6-methylmercaptopurine. Genetically
determined variations in 6-MP metabolism can produce significant
differences in efficacy and safety.
88.6% had high enzyme activity, 11.1% had intermediate activity
and 0.3% had no detectable activity (Weinshilboum and Sladek,
1980). Germane to the issue of drug safety in children, 115 of the
subjects in this study were children, being on average 13 years
of age. The clinical relevance of this finding relates to the fact
that patients homogenous for low TPMT activity are at markedly
greater risk for dose-related toxicity such as neutropenia during
treatment with 6-mercaptopurine (Lennard et al., 1990).
The fact that this observation was made three decades ago
raises the question of why TPMT genotyping has not been a
part of routine care for children with cancer for longer than it
has (McLeod et al., 2000; Bomgaars and McLeod, 2005). One
pragmatic issue was that in some sense this discovery may have
come too soon for implementation into routine care. At the
time genotyping required significantly more blood—and more
expense—than currently. The usual method of monitoring for
neutropenia—doing a complete blood count—was a reliable and
very inexpensive method of monitoring, notably as the initial
considerations were this was only germane for the 0.3% of the
population homozygous for low TPMT activity and as there were
(and are) well established evidence-based protocols to monitor
for this very complication. There has been active discussion and
debate as to the extent to which dosage adjustment was needed in
the much larger of patients heterozygous for the low activity allele
(Relling et al., 1999). It has become increasingly apparent that
dose alterations may be needed in other groups than the homozy-
gous low activity group. As an example, patients with high activity
may need an increased dose of 6-mercaptopurine, while the risk
of a secondary malignancy may be related at least in part to
variable TPMT activity (Bo et al., 1999; Adam de Beaumais and
Jacqz-Aigrain, 2012). The role of gene-gene interactions in deter-
mining toxicity and the importance of a multi-factorial approach
to risk assessment including consideration of age and concur-
rent therapy in addition to genotypic variability has highlighted
the importance of genotyping, not only in the setting of cancer
but also for other indications for thiopurines in children such as
inflammatory bowel disease (Dorababu et al., 2012; Mazor et al.,
2013).
More recently, pharmacogenomics has provided insights into
other adverse events associated with therapy for children’s can-
cer. Cisplatin is a platinum-based chemotherapeutic agent whose
mechanism of action is to form in vivo cross-linkages to DNA in
turn trigger apoptosis (Macciò and Madeddu, 2013). Cisplatin
is a highly effective chemotherapeutic drug used for the treat-
ment of a number of solid tumors in both adults and children.
While a very useful chemotherapeutic agent, cisplatin produces
many adverse events, one of the most serious being ototoxicity
(Rybak et al., 2009; Brock et al., 2012). The known risk factors
including concurrent therapy with other ototoxic drugs, male
gender and age; particularly germane to child health care, chil-
dren under the age of 5 have been found to have a 20 fold greater
risk for ototoxicity than do adults (Langer et al., 2013). The
mechanism of this ototoxicity—and which particular children
are at risk—are not known although it is believed that oxidant
stress may be a key determinant in this toxicity. Recently we con-
ducted a study through a cross-Canada network of 16 pediatric
academic health care center in cases of severe cisplatin-induced
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hearing loss and drug-matched controls were identified and
studied (Ross et al., 2009). We found an association between
tag single nucleotide polymorphisms (SNPs) in the thiopurine
S-methyltransferase (TPMT) gene (rs12201199, rs1142345 and
rs1800460) and in the catechol-O-methyltransferase (COMT) gene
(rs9332377) with severe cisplatin induced ototoxicity (Ross et al.,
2009; Pussegoda et al., 2013). This finding has been validated in
a replication cohort but interestingly has not been validated in a
murine model of cisplatin-induced ototoxicity (Pussegoda et al.,
2013; Yang et al., 2013). We have modeled the predictive value of
these alleles and our data suggest that children with no risk alleles
have at the 5 year mark a 60% chance of having normal hear-
ing, vs. children with three or more risk alleles who have a very
high risk of having demonstrable hearing loss at the 5 year mark.
Economic analysis has suggested that pharmacogenomic testing
at the onset of chemotherapy can provide significant savings in
health care costs (Dionne et al., 2012).
The approach taken to determine these SNPs should be noted.
While one approach to studying pharmacogenomic sources of
variability in drug disposition and toxicity it to use s study
strategy tightly focused on pathways known to be mechanisti-
cally important in drug disposition and adverse events, we used
a broader strategy given that the pathophysiology of cisplatin-
induced hearing loss is not well understood. Consequently we
studied 1949 SNPs in patients and controls to assess 220 genes
involved in drug metabolism and disposition in addition to
disease-specific genes that were related to pathways impacted by
cisplatin therapy (Ross et al., 2009). This broad approach allowed
us to not only potentially identify patients at risk but also to begin
mechanistic studies to better understand how ototoxicity evolves
and, potentially, how to prevent this.
We have used this approach to study the toxicity of another
important class of chemotherapeutic agents, the anthracyclines.
The anthracyclines a class of antitumour antibiotics; their mech-
anism of action involves intercalation between base pairs on
DNA/RNA strands, inhibition of topoisomerase II, generation of
iron-mediated free oxygen radicals and inducing histone evic-
tion from chromatin (Gewirtz, 1999). The anthracyclines are
extremely effective chemotherapeutic agents, and form the cor-
nerstone of therapy for many common cancers in children,
including most of the lymphotoreticular malignancies (van Dalen
et al., 2011). In common with many potent chemotherapeutic
agents, anthracyclines are associated with a number of seri-
ous adverse effects, of which the most feared long-term adverse
event is cardiotoxicity (Kucharska et al., 2012; Harake et al.,
2012; de Ville de Goyet et al., 2012). The known risk fac-
tors for anthracycline-induced cardiotoxicity include cumulative
dose, female gender, higher dose rate, cranial irradiation and age.
Similar to cisplatin, anthracyclines are associated with a markedly
higher risk of toxicity in young children vs. adults (Harake et al.,
2012; de Ville de Goyet et al., 2012). Anthracycline-induced car-
diotoxicity is associated with significant morbidity and an appre-
ciable mortality rate. Thus, identifying patients at risk would be
of obvious advantage (Zerra et al., 2013).
Our group has studied this problem using a similar to that
we used for our research with respect to cisplatin induced oto-
toxicity. Using a national network to identify cases of severe
anthracycline-induced cardiotoxicity and drug-matched controls,
we identified a series of SNPs associated with anthracyline-
induced cardiotoxicity (Visscher et al., 2012). These vari-
ants include SNPs which appear to confer protection from
anthracycline-induced cardiotoxicity such as loss-of-function
SNPs for influx transporters which we believe bring anthracy-
clines into cardiac myocytes (Table 3) (Visscher et al., 2012).
We have also identified risk variants which increase the risk of
anthracycline-induced cardiotoxicity such as loss-of-function for
efflux transporters which we believe export anthracyclines from
cardiac myocytes (Table 3) (Visscher et al., 2012). We have repli-
cated these findings in a cohort of children from the Netherlands
and are currently validating these findings using cellular models
(Visscher et al., 2013).
This research has yet to be translated into changes in clinical
practice but points to the potential for pharmacogenomic work to
enhance drug safety among children with cancer. Other drugs for
whom pharmacogenomic studies are likely to be fruitful include
cyclophosphamide and ifosfamide (Huang et al., 2000; Pinto
et al., 2009; Johnson et al., 2013). Renal injury is a common and
important long-term complication of ifosfamide therapy which
is also much more common among children with cancer than
among older patients. Our group has had extensive experience
with this agent and we and others have demonstrated both that
nephrotoxicity appears to be mediated by generation of reactive
metabolites produced by pathways known to be subject to genetic
polymorphisms and that N-acetylcysteine has potential as a pre-
ventive strategy to reduce the risk for and severity of ifosfamide-
induced nephrotoxicity (Chen et al., 2008; Hanly et al., 2009,
2011). However, this is a resource-intensive and not entirely risk-
free strategy, and thus pharmacogenomic approaches which could
identity patients at risk would be of great use in the practi-
cal implementation of this approach to reducing an important
toxicity associated with ifosfamide therapy, nephrotoxicity.
ANALGESIC THERAPY
Over the past two decades it has been appreciated that historically
pain has been under-treated in children and that this has been
associated with poor outcomes (Taddio et al., 2010; Twycross,
2010). The WHO “Pain Ladder” describes a step-wise approach
to pain management which includes the use of codeine, a
Table 3 | Risk and protective SNPs for anthracycline cardiotoxicity.
Gene SNP Predictive role
UGT1A6 rs6759892 Risk
ABCB4 rs1149222 Risk
ABCC1 rs4148350 Risk
HNMT rs17583889 Risk
SCL28A3 rs78583889 Protective
FMO2 rs2020870 Protective
SPG7 rs2019604 Protective
SLC10A2 rs9514091 Protective
SLC28A3 rs4877847 Protective
Derived from Visscher et al. (2012).
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weak opiate that has been one of the most commonly used
opiates in children (Eddy et al., 1969; WHO, 1998). Codeine
is the second most abundant alkaloid in opium and there are
many reasons it has been commonly used for pain relief in
children; it is inexpensive and is available orally in a stable
formulation in both liquid and tablet form. Codeine itself is
3-methylmorphine and is a pro-drug. After codeine is taken,
it enters the liver through the portal circulation where it is
metabolized via both Phase I and Phase II pathways (Desmeules
et al., 1991). Codeine de-methylated (mediated by CYP2D6)
produces morphine, the major compound by which codeine
exerts its analgesic effects (Sindrup and Brosen, 1995). Codeine
conjugation by Glucuronyltransferase (specifically, UDP-
Glucuronosyltransferase-2B7) produces codeine-3-glucuronide
and codeine-6-glucuronide, 6-glucuronide being pharmacog-
ically active (Madadi and Koren, 2008). Codeine metabolism
by CYP2D6 typically only accounts for 5% of the dose, with
further metabolism via glucuronidation producing primarily
morphine-3-glucuronide and a much smaller amount morphine
6-glucuronide, the 6-glucuronide also being pharmacologically
active.
Opiate toxicity, with the classical presentation of coma, mio-
sis, and bradypnea, is a well-known adverse event seen with
codeine overdose (Von Muhlendahl et al., 1976). This was felt
to be very uncommon in usual therapeutic use. However, in
2006 Dr. Gideon Koren et al. described a therapeutic tragedy
in which a breast-fed infant who of opiate toxicity related to
maternal use of codeine post episiotomy (Koren et al., 2006).
A detailed investigation of blood and breast milk coupled with
genetic studies demonstrated that, despite the use of prescribed
and conventional doses of a codeine-acetaminophen combination
product by the mother, that the infant had very high concentra-
tions of morphine in the blood, post-mortem blood morphine
concentration being 245 nM/L (Koren et al., 2006). To put this in
context, chronic high-dose opiate therapy produces blood con-
centrations in the range of 190 nM/L (Goucke et al., 1994). The
reason for this very high morphine concentration became appar-
ent when pharmacogenomic studies were conducted. The mother
was an ultrarapid metabolizer for CYP2D6 who metabolized sig-
nificantly more codeine to morphine than expected, validated by
studies of morphine concentration in breast milk (Koren et al.,
2006).
CYP2D6 has been recognized as a polymorphic enzyme for
some time. There are three three distinct phenotypes—extensive
metabolizers (EMs), poor metabolizer (PMs) and ultrarapid
metabolizers (UMs) as the result of extensive polymorphisms
for the gene encoding CYP2D6 (PheNeafsey et al., 2009). There
are more than 80 recognized alleles for CYP2D6, with many
of these producing the PM phenotype (Crews et al., 2012).
These polymorphisms show variable expression in different
populations (Bernard et al., 2006; Teh and Bertilsson, 2012).
The importance of these polymorphisms in the metabolism of
codeine was not appreciated initially. Codeine was first isolated
in France in 1832, this being in a population among whom
the UM polymorphism is uncommon. As the use of codeine
has expanded it has become more common in populations
with much higher rates of the UM genotype. Thus it is not
surprising that problems with codeine toxicity have emerged—
not only among newborns, but also among older children fol-
lowing surgery (Madadi et al., 2008; Ciszkowski et al., 2009; Kelly
et al., 2012).
In contrast to the situation with respect to childhood cancer,
these pharmacogenomic observations have resulted in a sharp
response from drug regulatory agencies and a change in prac-
tice, with codeine use in children dropping sharply in many
regions (Food and Drug Administration, 2012). Many hospital
formularies have dropped codeine - sometimes with careful delib-
eration and sometimes with changes that less than fully thought
out (for example, replacing codeine with oxycodone—which is
O-demethylated by CYP2D6). A common change has been the
replacement of codeine with morphine, probably sensible as most
of the analgesic activity of codeine is related to metabolism to
morphine (Poulsen et al., 1996). Of note, these changes occurred
within five years of the publication of the index case that first
triggered concerns as to genetically determined toxicity in chil-
dren (Food and Drug Administration, 2012; Friedrichsdorf et al.,
2013). It is worth considering why this happened so quickly
with codeine as compared to the chemotherapeutic agents. In
the case of chemotherapeutic agents, pharmacogenomic inves-
tigations have occurred in the context of children with severe
disease with highly mortality for whom effective therapeutic reg-
imens have dramatically changed outcome. Thus any change is
likely to be carefully evaluated before changes in clinical practice
occur. In contrast, while deaths in the context of codeine therapy
have been infrequent they occurred in healthy children either after
delivery or after procedures generally believed to be safe.
The case of codeine has highlighted the potential importance
of pharmacogenomics for safe and effective analgesic therapy for
children and how these variations can rapidly impact on pub-
lic policy and clinical practice and suggests new directions for
research in with respect to other analgesics and clinical practice
implementation (Fukuda et al., 2013; Kelly et al., 2013).
DRUG HYPERSENSITIVITY
One of the most feared patterns of adverse drug reactions
among children is drug hypersensitivity such as Stevens-Johnson
Syndrome and Toxic Epidermal Necrolysis (Elzagallaai et al.,
2011). These are unpredictable, delayed onset, often very severe
adverse events that occur not uncommonly and are associ-
ated with serious morbidity and mortality (Rieder, 2009). These
adverse events occur with some of the drugs most commonly
used for certain populations, such as carbamazepine, and to drugs
which are being used more commonly such as sulfonamides (for
example, for the therapy of community-acquired methicillin-
resistant Staphylococcus aureus). Thus, developing strategies to
evaluate risk at the onset of therapy would be of obvious utility
and as well would provide important insights into the pathophys-
iology of these adverse events, which remains unclear (Rieder,
2012).
Initial pharmacogenomic studies in drug hypersensitivity have
been somewhat disappointing (Rieder, 2012). Over the past
decade the association has been made between drug hypersen-
sitivity and certain haplotyes (Table 4) (Phillips et al., 2011).
The use of these haplotypes to screen patients prior to initiating
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Table 4 | HLA Associations with adverse drug reactions
Haplotype Drug Adverse event Ethnic group
HLA-B*1502 Carbamazepine Drug hypersensitvity Han Chinese
HLA-A*3101 Carbamazepine Drug hypersensitvity European
HLA-B*5701 Abacavir Drug hypersensitvity Mixed ancestry
HLA-B*5801 Allopurinol Severe skin rash Various populatons
HLA-B*3505 Nevirapine Skin rash Thai
HLA-B*5701 Flucloxacillin Liver injury Mixed ancestry
HLA-B*1502 Phenytoin Drug hypersensitvity Han Chinese, Thai
Derived from Phillips et al. (2011).
therapy has been proven as an effective strategy—most notably
for abacavir, for whom the use of screening for HLA-B∗5701 has
reduced the risk of serious skin rash from 3% to zero (Phillips
et al., 2011). However, this strategy also means that a number
of patients for whom the drug would be effective and safe have
been excluded from therapy—for example, in the case of carb-
mazepine as many as 6—8 patients who could have taken the drug
vs. those who would have had a serious skin rash - suggesting
that more detailed pharmacogenomic analysis would be helpful in
more precisely identifying which patients would benefit and who
would be at risk from therapy. As well, pharmacogenomic studies
have the potential as noted above in helping to provide mech-
anistic insights that can direct both preventive and therapeutic
strategies.
PERSONALIZED MEDICINE FOR CHILDREN
The examples cited above should not be taken to mean they are
the only care areas in which pharmacogenomics for children has
the potential to improve drug safety. There are a number of other
drugs commonly used in children for whom pharmacogenomic
studies offer great potential in improving safety and efficacy
(Downing et al., 2012; Lima et al., 2013; Vear et al., 2013). In
some cases—for example, warfarin—pharmacogenomic studies
in adults have already demonstrated the utility of incorporating
pharmacogenomic data along with other variables in improv-
ing efficacy and reducing risk of adverse effects, albeit with some
controversy (Siegel, 2012; Pirmohamed et al., 2013).
There is perhaps no area in which there is greater need for bet-
ter defining therapy than pediatric psychopharmacology (Arango,
2011; Stroeh and Trivedi, 2012; Kimmel et al., 2013; Noam et al.,
2013). While the use of psychoactive drugs in children has over
the past two decades increased proportionately more than that of
any other drug class, this increase in utilization has often occurred
in the absence of robust evidence for efficacy, optimal dosage
and safety. Given the large and increasing population of children
receiving treatment for central nervous systems conditions—
from epilepsy to depression—studies in defining optimal and safe
therapy are urgently needed, and pharmacogenomics has con-
siderable potential in not only defining efficacy and safety but
also in asking key questions with respect to fundamental mech-
anisms underlying disorders involving the central nervous system
in children vs. adults.
When considering these studies there are serious questions
that need to be asked, such as which should be priority drug
targets for study? This issue has been given careful thought by a
number of investigators and algorithms have been developed to
identify targets for further study (Shaw et al., 2013). While there
are practical issues to undertake these studies, such as ensuring
adequate numbers of patients, the development of national and
international networks provide strategies that can address these
issues (Loo et al., 2010). Future studies will need to include phar-
macoeconomic evaluation as well as consideration of the evolving
ethical climate under which clinical and genetic research is con-
ducted (Wong et al., 2010; Donnan et al., 2011). In the case of
pharmacoeconomic studies a critical element as health care sys-
tems globally struggle with the challenge of determining how to
best allocate scant health care resources (Norbert and Roses, 2003;
Hedgecoe, 2006; Rogausch et al., 2006; Fargher et al., 2007; Wong
et al., 2010; Donnan et al., 2011; Pirmohamed, 2011).
ETHICAL CONSIDERATIONS
The use of pharmacogenomic information to inform diagnosis
and guide therapy for children provides a series of interesting
and unique ethical challenges. Implicit in therapy for children is
the ethical conflict that the person giving consent—a parent or
guardian—is not the one receiving the therapy. As an example,
research conducting in the setting of childhood cancer demon-
strated that when facing difficult therapeutic choices parents have
difficulty in distinguishing their understanding of the situation
from their child’s experiences (Levi et al., 2000). This is further
compounded by the controversy as to what constitutes assent and
at which age assent can and should be obtained. This situation is
very complicated in the United States, where the age of legal assent
varies from state to state (Coleman and Rosoff, 2013).
A major additional challenge germane to pharmacogenomics
is the concern that secondary information obtained during
genetic testing may have a distant impact on access to insur-
ance, employment or care (Netzer and Biller-Andorno, 2004).
Again, this is an even more pressing issue when the person giv-
ing consent is not the person for whom the information is being
obtained. An attempt to address this has been made with legisla-
tion such as Public Law 110–233 (110th Congress), the Genetic
Information Non-discriminatory Act (GINA). This was signed
into law in the United States Congress in 2008 with the intent
of preventing insurance and employment discrimination on the
basis of genetic testing (Dressler and Terry, 2009). While this was
an honest and sincere effort to address this important issue with
wide popular support—passing through the US Congress with
only one dissenting vote—there are concerns that the rapid pace
of development of genetic testing may render parts this legislation
obsolete.
Our group has worked with parent groups in studying the eth-
ical acceptability of genetic testing for their children and have
found that their most important concerns were securing proper
informed consent including ensuring that they had enough infor-
mation to make a well informed decision. An additional concern
was that their health care providers had the background and
training to make appropriate decisions based on the results of
genetic testing. This speaks strongly to the importance of patient
and parent empowerment as well as to the need for including con-
siderations on how to use genetic information for diagnosis and
therapy in undergraduate and postgraduate health care profes-
sional training.
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FUTURE DIRECTIONS
One of the major directions that medical education and care has
made over the past several decades has been in the development
of evidence-based medicine and in clinical guidelines informed
by evidence to enhance and optimize patient care. Our group
and others are working to incorporate the use of genetic infor-
mation into guidelines on the diagnosis and therapy of common
and important conditions. One area in which this is most likely to
take fruit in the short term is the area of pediatric oncology, where
guidelines are being written to incorporate the results of pharma-
cogenomic analysis into the initial assessment, monitoring, and
therapy of children with cancer. Cancer and chronic disease offer
the potential for pharmacogenomic analysis as therapy is being
planned, which provides the opportunity given real-time turn-
around of genetic testing to be able to better define which children
are at special risk for adverse drug events and to better plan how
therapy might be more closely monitored or modified in these
children.
The potential of pharmacogenomics in improving therapy
for children also applies in the development of new therapeutic
agents, for which the potential for genetic variation impacting on
efficacy and/or safety should be part of the research considera-
tions and clinical trial design. Historically therapy for children has
lagged behind therapy for adults—it is important that this should
not be the case in the era of personalized medicine.
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